Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Ducreux, M.; Abou-Alfa, G.; Ren, Z.; Edeline, J.; Li, Z.; Assenat, E.; Rimassa, L.; Blanc, J.; Ross, P.; Fang, W.; Hu, S.; Zhang, T.; Tran, A.; Pan, H.; Yen, C.; Wu, J.; Li, V.; Chica-Duque, S.; Merle, P.; Cheng, A. |
| Abstract Title: | Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma |
| Meeting Title: | ESMO 23rd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2021 Jun 30-Jul 3 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-07-01 |
| Start Page: | S217 |
| Language: | English |
| ACCESSION: | WOS:000670004200331 |
| DOI: | 10.1016/j.annonc.2021.05.005 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O-1 -- Source: Wos |
